Clinical Trial Update: DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating DEB-TACE in combination with lenvatinib, sorafenib, or a PD-1 inhibitor for unresectable hepatocellular carcinoma is ongoing with unkno…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• DEB-TACE
• Lenvatinib (lenvatinib)
• PD-1 inhibitor
• Sorafenib (Sorafenib)

Snippet

Sponsor: Guangxi Medical University | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: UNKNOWN